ADXS Advaxis Inc.

0.63
+0.09  (+17%)
Previous Close 0.54
Open 0.55
Price To Book 0.91
Market Cap 37,954,850
Shares 60,245,793
Volume 2,351,080
Short Ratio
Av. Daily Volume 4,342,247
Stock charts supplied by TradingView

NewsSee all news

  1. Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

    PRINCETON, N.J., March 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an

  2. Advaxis to Present at the 2020 LD Micro Virtual Conference

    PRINCETON, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that

  3. Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

    First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA® Partial response observed in one patient

  4. Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

    ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting Patient who previously progressed on pembrolizumab showed stable

  5. Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

    Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to an estimated 11 months with Standard of Care Median

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Enrollment to be terminated - noted November 2, 2018.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Phase 1 presentation at ASCO Genitourinary Cancers Symposium February 13, 2020 noted median overall survival (95% CI) of 33.7 months.
ADXS-PSA and Keytruda - KEYNOTE-046
Castrate-resistant prostate cancer
Phase 3 trial closed - noted June 27, 2019.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
ADXS-HER2
HER2-driven malignancies - cancer
Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
Axalimogene filolisbac
Anal cancer (FAWCETT)
Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-NEO
Non-small cell lung cancer (NSCLC)
Phase 1 data noted 50% (3 of 6) of evaluable patients from monotherapy arm and 1/1 patients on combo arm (Keytruda) showed stable disease - February 20, 2020.
ADXS-HOT 503
Non-small cell lung cancer (NSCLC)

Latest News

  1. Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

    PRINCETON, N.J., March 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an

  2. Advaxis to Present at the 2020 LD Micro Virtual Conference

    PRINCETON, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that

  3. Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

    First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA® Partial response observed in one patient

  4. Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

    ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting Patient who previously progressed on pembrolizumab showed stable

  5. Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

    Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to an estimated 11 months with Standard of Care Median

  6. Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

    PRINCETON, N.J. and MENLO PARK, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,

  7. Data on Advaxis' Clinical Programs to be Presented at Upcoming Medical Meetings

    PRINCETON, N.J., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the

  8. Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering

    PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS) (the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today

  9. Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer

    PRINCETON, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the

  10. Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31,

  11. Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive

  12. Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer

    Immune response data from its HOT Lung program expected early 2020 Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today

  13. Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the

  14. Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial

     Median overall survival for ADXS-PSA in combination with KEYTRUDA® increased to 33.6 months from previously reported 21.1 months Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the

  15. Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial

  16. Advaxis, Inc. Issues Letter to Shareholders

    Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer, Kenneth A.